Viatris has made a play to expand its branded ... OPUS-2 – that are comparing the drug to placebo when the drug is given on top of standard therapy in around 800 patients with moderate to ...

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain ...

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic ...

Viatris (VTRS) announced it has filed applications to the Ministry of Health, Labor and Welfare for approval of Effexor SR Capsules, a ...

the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company's Indore, India, facility. Still, Viatris downplayed the ...

In February, VTRS reported lower-than-expected fourth-quarter results, wherein the top and bottom lines missed their respective estimates. The guidance for 2025 was disappointing as well. Viatris ...

Such forward-looking statements may include statements regarding the receipt or timing of regulatory approvals; the outcome of clinical trials; the filing of our supplemental New Drug Applications ...

April 17, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, ...

the Viatris class action lawsuit charges Viatris and certain of Viatris' top executives with violations ... ramifications of the failed U.S. Food and Drug Administration ("FDA") inspection fell ...